The United States Patent and Trademark Office (“USPTO”) has granted the fifth patent (Patent No. 12,098,149) in a comprehensive series, securing broad protection for a novel crystal isoform of ...
The United States Patent and Trademark Office (“USPTO”) has granted the fifth patent (Patent No. 12,098,149 ... two clinically-validated targets: 5-HT4 receptor agonism and D2 receptor ...
The United States Patent and Trademark Office (“USPTO”) has granted the fifth patent (Patent No. 12,098,149 ... two clinically-validated targets: 5-HT4 receptor agonism and D2 receptor ...
The United States Patent ... the fifth in a series covering naronapride, with its novel crystal isoform; a potential best-in-class, orally administered pan-GI prokinetic agent. Naronapride functions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback